Depression, anemia and health-related quality of life in chronic hepatitis C

Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas Wise, Sean C. Robbins, Zobair M. Younossi

Research output: Contribution to journalArticle

Abstract

Background/Aims: Hepatitis C (HCV) infected patients have significant health-related quality of life (HRQL) impairment which worsens during anti-viral therapy. Our aim was to examine the association of HRQL with treatment-induced depression and anemia. Methods: Two hundred and seventy-one HCV patients who received pegylated interferon alfa 2b and ribavirin were included. Data on HRQL, depressive symptoms, laboratory values and socio-demographic characteristics were collected. Results: Mean age was 47.1±6.5, 69% were male, and 73% were White. HCV patients' HRQL declined during anti-viral therapy but returned to or exceeded baseline levels within 24 weeks of completion. Anemia and depression were both associated with HRQL impairment. The effects of depression on HRQL were strong; once depression scores were included other factors were no longer significant. Patients' depressive symptoms tended to increase during the initial half of treatment regimen. Those with higher body mass index (BMI), cirrhosis, and women reported more HRQL impairments. HRQL scales were generally not associated with alcohol abuse, age, race, ALT and HCV RNA levels. Conclusions: Anti-viral therapy for HCV is associated with diminished HRQL. Although anemia and depression were associated with this impairment, depression was the most consistent predictor. Future studies are needed to see whether proactive management of these side effects can improve patients' HRQL and the efficacy of antiviral therapy for hepatitis C.

Original languageEnglish (US)
Pages (from-to)491-498
Number of pages8
JournalJournal of Hepatology
Volume44
Issue number3
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Anemia
Quality of Life
Depression
Hepatitis C
Therapeutics
Ribavirin
Alcoholism
Antiviral Agents
Body Mass Index
Fibrosis
Demography
RNA

Keywords

  • Anemia
  • Depression
  • HCV
  • HRQL

ASJC Scopus subject areas

  • Hepatology

Cite this

Dan, A. A., Martin, L. M., Crone, C., Ong, J. P., Farmer, D. W., Wise, T., ... Younossi, Z. M. (2006). Depression, anemia and health-related quality of life in chronic hepatitis C. Journal of Hepatology, 44(3), 491-498. https://doi.org/10.1016/j.jhep.2005.11.046

Depression, anemia and health-related quality of life in chronic hepatitis C. / Dan, Amy A.; Martin, Lisa M.; Crone, Cathy; Ong, Janus P.; Farmer, Denise W.; Wise, Thomas; Robbins, Sean C.; Younossi, Zobair M.

In: Journal of Hepatology, Vol. 44, No. 3, 01.03.2006, p. 491-498.

Research output: Contribution to journalArticle

Dan, AA, Martin, LM, Crone, C, Ong, JP, Farmer, DW, Wise, T, Robbins, SC & Younossi, ZM 2006, 'Depression, anemia and health-related quality of life in chronic hepatitis C', Journal of Hepatology, vol. 44, no. 3, pp. 491-498. https://doi.org/10.1016/j.jhep.2005.11.046
Dan, Amy A. ; Martin, Lisa M. ; Crone, Cathy ; Ong, Janus P. ; Farmer, Denise W. ; Wise, Thomas ; Robbins, Sean C. ; Younossi, Zobair M. / Depression, anemia and health-related quality of life in chronic hepatitis C. In: Journal of Hepatology. 2006 ; Vol. 44, No. 3. pp. 491-498.
@article{965c1c8c7da14f26bf45741ce0f4c653,
title = "Depression, anemia and health-related quality of life in chronic hepatitis C",
abstract = "Background/Aims: Hepatitis C (HCV) infected patients have significant health-related quality of life (HRQL) impairment which worsens during anti-viral therapy. Our aim was to examine the association of HRQL with treatment-induced depression and anemia. Methods: Two hundred and seventy-one HCV patients who received pegylated interferon alfa 2b and ribavirin were included. Data on HRQL, depressive symptoms, laboratory values and socio-demographic characteristics were collected. Results: Mean age was 47.1±6.5, 69{\%} were male, and 73{\%} were White. HCV patients' HRQL declined during anti-viral therapy but returned to or exceeded baseline levels within 24 weeks of completion. Anemia and depression were both associated with HRQL impairment. The effects of depression on HRQL were strong; once depression scores were included other factors were no longer significant. Patients' depressive symptoms tended to increase during the initial half of treatment regimen. Those with higher body mass index (BMI), cirrhosis, and women reported more HRQL impairments. HRQL scales were generally not associated with alcohol abuse, age, race, ALT and HCV RNA levels. Conclusions: Anti-viral therapy for HCV is associated with diminished HRQL. Although anemia and depression were associated with this impairment, depression was the most consistent predictor. Future studies are needed to see whether proactive management of these side effects can improve patients' HRQL and the efficacy of antiviral therapy for hepatitis C.",
keywords = "Anemia, Depression, HCV, HRQL",
author = "Dan, {Amy A.} and Martin, {Lisa M.} and Cathy Crone and Ong, {Janus P.} and Farmer, {Denise W.} and Thomas Wise and Robbins, {Sean C.} and Younossi, {Zobair M.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1016/j.jhep.2005.11.046",
language = "English (US)",
volume = "44",
pages = "491--498",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Depression, anemia and health-related quality of life in chronic hepatitis C

AU - Dan, Amy A.

AU - Martin, Lisa M.

AU - Crone, Cathy

AU - Ong, Janus P.

AU - Farmer, Denise W.

AU - Wise, Thomas

AU - Robbins, Sean C.

AU - Younossi, Zobair M.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Background/Aims: Hepatitis C (HCV) infected patients have significant health-related quality of life (HRQL) impairment which worsens during anti-viral therapy. Our aim was to examine the association of HRQL with treatment-induced depression and anemia. Methods: Two hundred and seventy-one HCV patients who received pegylated interferon alfa 2b and ribavirin were included. Data on HRQL, depressive symptoms, laboratory values and socio-demographic characteristics were collected. Results: Mean age was 47.1±6.5, 69% were male, and 73% were White. HCV patients' HRQL declined during anti-viral therapy but returned to or exceeded baseline levels within 24 weeks of completion. Anemia and depression were both associated with HRQL impairment. The effects of depression on HRQL were strong; once depression scores were included other factors were no longer significant. Patients' depressive symptoms tended to increase during the initial half of treatment regimen. Those with higher body mass index (BMI), cirrhosis, and women reported more HRQL impairments. HRQL scales were generally not associated with alcohol abuse, age, race, ALT and HCV RNA levels. Conclusions: Anti-viral therapy for HCV is associated with diminished HRQL. Although anemia and depression were associated with this impairment, depression was the most consistent predictor. Future studies are needed to see whether proactive management of these side effects can improve patients' HRQL and the efficacy of antiviral therapy for hepatitis C.

AB - Background/Aims: Hepatitis C (HCV) infected patients have significant health-related quality of life (HRQL) impairment which worsens during anti-viral therapy. Our aim was to examine the association of HRQL with treatment-induced depression and anemia. Methods: Two hundred and seventy-one HCV patients who received pegylated interferon alfa 2b and ribavirin were included. Data on HRQL, depressive symptoms, laboratory values and socio-demographic characteristics were collected. Results: Mean age was 47.1±6.5, 69% were male, and 73% were White. HCV patients' HRQL declined during anti-viral therapy but returned to or exceeded baseline levels within 24 weeks of completion. Anemia and depression were both associated with HRQL impairment. The effects of depression on HRQL were strong; once depression scores were included other factors were no longer significant. Patients' depressive symptoms tended to increase during the initial half of treatment regimen. Those with higher body mass index (BMI), cirrhosis, and women reported more HRQL impairments. HRQL scales were generally not associated with alcohol abuse, age, race, ALT and HCV RNA levels. Conclusions: Anti-viral therapy for HCV is associated with diminished HRQL. Although anemia and depression were associated with this impairment, depression was the most consistent predictor. Future studies are needed to see whether proactive management of these side effects can improve patients' HRQL and the efficacy of antiviral therapy for hepatitis C.

KW - Anemia

KW - Depression

KW - HCV

KW - HRQL

UR - http://www.scopus.com/inward/record.url?scp=32444441241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32444441241&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2005.11.046

DO - 10.1016/j.jhep.2005.11.046

M3 - Article

C2 - 16427157

AN - SCOPUS:32444441241

VL - 44

SP - 491

EP - 498

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -